Pelitinib is used primarily in cancer research, particularly as an experimental tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). It shows potential in inhibiting tumor cell proliferation, especially in cancers driven by EGFR mutations, such as non-small cell lung cancer. Its ability to block signaling pathways involved in cell growth and survival makes it a candidate for targeted therapy studies. Research also explores its role in overcoming resistance to other EGFR inhibitors, enhancing the effectiveness of treatment in resistant cancer lines. Though not widely used clinically, it remains a valuable tool in oncology drug development and molecular pharmacology studies.